Vaccinomic approach for novel multi epitopes vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Almofti, Yassir A.; Abd-elrahman, Khoubieb Ali; Eltilib, Elsideeq E. M.

doi:10.1186/s12865-021-00412-0

Table 3 The predicted T helper cells epitopes, their antigenicity, allergenicity, toxicity and the population coverage from spike S protein and orf1ab polyprotein

From: Vaccinomic approach for novel multi epitopes vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Protein	Core peptide (Epitope)	Peptide	Start	End	Vaxijen antigenicity (0.4)	Allergenicity	Toxicity	Population coverage
Spike S protein	FELLHAPAT	FELLHAPATVCGPKK	515	529	0.5409	Nonallergen	Nontoxin	98.03%
	^aFAMQMAYRF	FAMQMAYRFNGIGVT	898	912	1.0278	Nonallergen	Nontoxin	98.93%
	FNFSQILPD	FNFSQILPDPSKPSK	800	814	0.5831	Nonallergen	Nontoxin	99.73%
	FGAISSVLN	FGAISSVLNDILSRL	970	984	0.5435	Nonallergen	Nontoxin	98.66%
	FNATRFASV	FNATRFASVYAWNRK	342	356	0.5609	Nonallergen	Nontoxin	99.23%
	LLFNKVTLA	LLFNKVTLADAGFIK	821	835	0.615	Nonallergen	Nontoxin	99.48%
	LLQYGSFCT	LLQYGSFCTQLNRAL	753	767	0.8188	Nonallergen	Nontoxin	99.21%
	NRALTGIAV	NRALTGIAVEQDKNT	764	778	0.5302	Nonallergen	Nontoxin	99.03%
	WTFGAGAAL	WTFGAGAALQIPFAM	886	900	0.4918	Nonallergen	Nontoxin	99.29%
orf1ab	^aVMYASAVVL	VMYASAVVLLILMTA	3683	3697	0.4778	Nonallergen	Nontoxin	98.28%
	^aFLLPSLATV	FLLPSLATVAYFNMV	3639	3653	0.5954	Nonallergen	Nontoxin	94.69%
	^aSLENVAFNV	SLENVAFNVVNKGHF	6453	6467	1.0488	Nonallergen	Nontoxin	97.84%
	FFYVLGLAA	FFYVLGLAAIMQLFF	2337	2351	0.8102	Nonallergen	Nontoxin	99.72%
	YELQTPFEI	YELQTPFEIKLAKKF	249	263	0.5468	Nonallergen	Nontoxin	98.88%
	LIYSTAALG	LIYSTAALGVLMSNL	2243	2257	0.5328	Nonallergen	Nontoxin	99.77%
	LRGTAVMSL	LRGTAVMSLKEGQIN	7052	7066	0.8822	Nonallergen	Nontoxin	99.82%
	LVQMAPISA	LVQMAPISAMVRMYI	2371	2385	1.0016	Nonallergen	Nontoxin	99.86%
	LVQSTQWSL	LVQSTQWSLFFFLYE	3594	3608	1.095	Nonallergen	Nontoxin	99.22%
	PLIVTALRA	PLIVTALRANSAVKL	4125	4139	0.9545	Nonallergen	Nontoxin	99.70%
	VLGLAAIMQ	VLGLAAIMQLFFSYF	2340	2354	0.6624	Nonallergen	Nontoxin	99.71%
	SACVLAAEC	SACVLAAECTIFKDA	2911	2925	0.5526	Nonallergen	Nontoxin	93.56%
	YVLGLAAIM	YVLGLAAIMQLFFSY	2339	2353	0.6002	Nonallergen	Nontoxin	99.87%

^athe overlapped epitopes between MHCI and MHCII molecules were used once in the vaccine construct as MHCI or MHCII epitopes

Back to article page

ISSN: 1471-2172

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Immunology

Contact us